Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Citi
Chinese Patent Office
Cantor Fitzgerald
Chubb
Fuji
Johnson and Johnson
Medtronic
Deloitte

Generated: June 18, 2018

DrugPatentWatch Database Preview

Sun Pharm Inds Ltd Company Profile

« Back to Dashboard

What is the competitive landscape for SUN PHARM INDS LTD, and when can generic versions of SUN PHARM INDS LTD drugs launch?

SUN PHARM INDS LTD has one hundred and seventeen approved drugs.

There are eight US patents protecting SUN PHARM INDS LTD drugs. There are two tentative approvals on SUN PHARM INDS LTD drugs.

There are thirty-one patent family members on SUN PHARM INDS LTD drugs in nineteen countries and one hundred and thirty-eight supplementary protection certificates in thirteen countries.

Summary for Sun Pharm Inds Ltd
International Patents:31
US Patents:8
Tradenames:90
Ingredients:87
NDAs:117

Drugs and US Patents for Sun Pharm Inds Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds Ltd AMOXICILLIN amoxicillin FOR SUSPENSION;ORAL 065113-002 Nov 29, 2002 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Sun Pharm Inds Ltd QUINAPRIL HYDROCHLORIDE quinapril hydrochloride TABLET;ORAL 076607-002 Dec 15, 2004 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Sun Pharm Inds Ltd CIPROFLOXACIN HYDROCHLORIDE ciprofloxacin hydrochloride TABLET;ORAL 075747-003 Jun 9, 2004 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Sun Pharm Inds Ltd ENALAPRIL MALEATE enalapril maleate TABLET;ORAL 075556-003 Aug 22, 2000 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Sun Pharm Inds Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sun Pharm Inds Ltd XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-005 Jul 11, 2012 5,908,838 ➤ Try a Free Trial
Sun Pharm Inds Ltd XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012 5,908,838 ➤ Try a Free Trial
Sun Pharm Inds Ltd XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-003 Jul 11, 2012 5,908,838 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Sun Pharm Inds Ltd

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,559,187 Liquid formulation of metformin ➤ Try a Free Trial
9,192,615 Method for the treatment of acne and certain dosage forms thereof ➤ Try a Free Trial
8,722,650 Extended-release minocycline dosage forms ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Sun Pharm Inds Ltd Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
30/2006 Austria ➤ Try a Free Trial PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SÄUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN
2008013 Lithuania ➤ Try a Free Trial PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REG. NO/DATE: EU/1/08/455/001-014 20080716
C0021 Belgium ➤ Try a Free Trial PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
1998 Austria ➤ Try a Free Trial PRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Fish and Richardson
Fuji
McKinsey
Harvard Business School
Accenture
Julphar
Baxter
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.